North China's Tianjin Municipality issued a license for medical services on Monday to a wholly foreign-owned, third-grade general hospital, the first of its kind in the country.
Suraksha Diagnostic Ltd, an integrated diagnostic chain based in Kolkata, has successfully raised ₹254 crore from anchor investors ahead of its initial public offering (IPO). This significant funding comes just a day before the company opens its IPO for public subscription. The IPO is set to attract considerable attention, given the robust backing from prominent mutual funds and the company’s extensive operational network.
Chinese authorities recently released revised rules on foreign investors' strategic investment in listed companies in a move to encourage foreign investors to make long-term and value investments in the country.
Auckland-based biotechnology company DNAiTECH has secured NZD $1 million in funding to advance its development of instant diagnostic tests that do not require a laboratory.
Massachusetts and Singapore-based biotechnology company Sunbird Bio has raised $14m to advance the clinical development of its blood-based diagnostic platform for neurological disorders and early-stage cancer.
Prenetics Global Limited (NASDAQ: PRE), a leading health sciences company, today announced that Tencent has made a strategic US$30 million investment in Insighta, a Hong Kong-based early cancer detection company. This investment values Insighta at US$200 million and underscores Tencent’s endeavor to advancing AI-powered innovations in healthcare.
Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.
Roche Diagnostics Suzhou signed an investment agreement with the Suzhou Industrial Park Administrative Committee on Wednesday, announcing it would invest 3 billion yuan (US$420 million) to expand its existing site in Suzhou, Jiangsu Province.
Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.
DELFI Diagnostics, Inc., a developer of accessible blood-based tests that deliver a new way to enhance cancer detection, today announced an equity investment by the Merck Global Health Innovation Fund (GHIF), the corporate venture capital arm of Merck & Co., Inc, known as MSD outside the United States and Canada. The capital will accelerate and expand DELFI's development and commercialization of its cancer detection solutions. DELFI's fragmentomics technology applies artificial intelligence (AI) to whole-genome sequencing data to compare an individual's cell-free DNA (cfDNA) patterns and characteristics against populations with and without cancer.
✔ All (62)
✔ Press release (0)
✔ Industry news (62)
Don’t miss important updates about the show and the in vitro diagnostic industry.
Sign-up for our newsletter today.
Copyright © 2025 GL events Ruihe (Shanghai) Exhibition Co., Ltd. All Rights Reserved. ( 沪ICP备12004745号-1 )
We deliver the latest IVD news straight to your inbox. Stay in touch with CACLP News.
sign-up for our newsletter today.
To ensure our newsletter hit your inbox, make sure to add @caclp.com to your safe senders list. And, as always, feel free to contact
us with any questions and thanks again for subscribing.